Description
Lipoxen is a leading biopharmaceutical company operating from the UK that develops high-value, differentiated pharmaceutical products in the fields of protein drugs, vaccines and anti-cancer drugs.
The company has developed a range of proprietary patented technologies that are being used to create a new generation of drug and vaccine products with improved performance. Lipoxen's technologies include: PolyXen® - Protein drug delivery, ImuXen® - DNA, protein and polysaccharide vaccines and VesicALL® - Anti-cancer drugs using liposomal entrapment.
Share Price
In-depth Lipoxen Proactive Investors Articles
Recent Lipoxen news
- 21/06/2010 Lipoxen extends PolyXen patent family in the US
- 14/06/2010 Lipoxen and Baxter confident that PolyXen-based haemophilia treatments will move into clinical devel
- 26/05/2010 Lipoxen expands its US DNA Vaccine Patent for ImuXen
- 26/05/2010 Lipoxen expands its US DNA Vaccine Patent for ImuXen
- 28/04/2010 Lipoxen receives positive results for ImuXen candidates for influenza and malaria
Presentations & Company Media
No Documents available.
Related Research & Media
No Documents available.
Company Statement:
Lipoxen develops and commercialises high-value, differentiated protein, vaccine and anti-cancer drug product candidates. The company’s strategy is to identify product candidates and to take them from an early stage of development into clinical trials.
At the appropriate stage of clinical development, Lipoxen outlicenses these protein, vaccine and anti-cancer drug product candidates to a partner. Partners are selected according to their ability to complete late phase clinical trials, obtain relevant regulatory approvals, manufacture the products and market them effectively.
Lipoxen’s three main technologies, PolyXen®, ImuXen® and VesicALL® are used as a platform for the company to:
- Develop its own protein, vaccine and anti-cancer new product candidates
- Co-develop new product candidates with partners
- Enable partners to improve their proprietary products
- Help partners to manage their product lifecycles more effectively
Current Operations:
Lipoxen has developed a range of proprietary patented technologies that are being used to create a new generation of drug and vaccine products with improved performance. Lipoxen’s technologies include:
PolyXen® for protein drug delivery
PolyXen® is a versatile enabling technology that uses the biopolymer polysialic acid to prolong the active life and improve the pharmacokinetics of therapeutic peptides and proteins, as well as conventional small molecule drugs. PolyXen® is potentially a next generation method to PEGylation for the delivery of protein drugs. (Read More)
ImuXen® for vaccine delivery
ImuXen® is an advanced enabling technology that uses liposome-based constructs to boost the effectiveness of DNA, protein and polysaccharide vaccines. ImuXen® can achieve protective immunity in a single dose. (Read More)
VesicALL® for anti-cancer drug delivery
VesicALL® is a highly efficient enabling technology for the formulation of anti-cancer treatment and other drugs using liposomal entrapment. Its proprietary method has increased the range of drugs which can be formulated in this way. (Read More)
Our new product candidates
Lipoxen is also developing its own range of proprietary product candidates, based on products already in the market and which incorporate these new technologies. Product candidates which are currently under development include:
| ErepoXen® | Potential treatment to maintain the red blood cell population and prevent anaemia |
| StimuXen™ | Potential treatment for neutropenia (a deficiency in white blood cells associated with myelosuppressive chemotherapy) |
| InferoXen ® | Potential treatment for hepatitis C |
| SuliXen® | Potential treatment for type II diabetes |
| LipoNeu™ | Potential vaccine for streptococcus pneumoniae (a cause of meningitis in children and pneumonia in adults) |
| LipoTet™ | Potential oral tetanus vaccine |
| HepaXen™ | Potential hepatitis B vaccine |
| LipoRab™ | Potential rabies vaccine |
| LipoTaxen® | Potential anti-cancer drug |
Management
Sir Brian Richards, CBE, BSc, PhD, DSc - Non-Executive Chairman
Scott Maguire - Chief Executive Officer
Professor Gregory Gregoriadis PhD, DSc - Chief Scientific Officer
Dr Dmitry D Genkin - Non-Executive Director
Mr Colin William Hill, ACMA - Chief Financial Officer
Mr Firdaus Jal Dastoor, FCS - Non-executive Director
No Image Mr Igor Nikolaev - Non-Executive director
Available
For more information on Lipoxen's Directors click here
For information on Lipoxen's Senior Management click here
Major Shareholders
Number of Securities in Issue
171,913,776 Ordinary Shares of 0.5p.
| Significant Shareholders | Number of shares | % |
|---|---|---|
| FDS Pharma Ass & related parties | 41,965,050 | 24.41% |
| Serum Institute of India Ltd & related parties | 33,566,415 | 19.53% |
| Pershing Nominees Limited A/C AGCLT | 8,905,420 | 5.18% |
| Baxter Healthcare SA | 7,325,470 | 4.26% |
| Chase Nominees Limited | 7,000,000 | 4.07% |
| Barclayshare Nominees Ltd | 6,195,770 | 3.60% |
The percentage of the Company's shares that is not in public hands is 49.88%
There are no restrictions on the transfer of the Company's shares.
(This information was last updated on 29 May 2010)
Updated from Lipoxen's website on 10th June 2010
For further investor information click here
Contact Information
Management Offices
Lipoxen PLC
18 Pall Mall
2nd Floor
London
SW1Y 5LU
United Kingdom
Tel : +44(0) 20 7389 5015
Fax: +44(0) 20 7389 5011
Email info@lipoxen.com
Laboratories
Lipoxen Technologies Ltd
London Bioscience Innovation Centre
2 Royal College Street
London
NW1 0NH
United Kingdom
Tel : +44(0) 207 691 3581
Corporate Information
Nominated Advisors
Singer Capital Markets Limited
One Hanover Street
London
W1S 1YZ
Company Brokers
Noble & Company Limited
5th Floor
120 Old Broad Street
London
EC2N 1AR
PR Advisors
Buchanan Communications Limited
45 Moorfields
London
EC2Y 9AE
Investors interested in Lipoxen recently viewed:
- Access Pharmaceuticals (OTCBB: ACCP)
- Advanced Cell Technology (OTCBB: ACTC)
- Alliance Pharma (AIM: APH)
- Amphion Innovations (LON: AMP)
- Asterand (LSE: ATD)
- Biocompatibles (LSE: BII)
- BioNeutral Group (OTCBB: BONU)
- Bionomics (ASX: BNO)
- Circadian Technologies Limited (ASX: CIR)
- CogState (ASX: CGS)
- e-Therapeutics plc (AIM: ETX)
- Eco Animal Health Group Plc (AIM: EAH)
- Epistem (AIM: EHP)
- ImmuPharma PLC (AIM: IMM)
- Medical Australia Limited (ASX: MLA)
- Oxford Nutrascience (AIM: ONG)
- Renovo Group Plc (LSE: RNVO)
- Rexahn Pharmaceuticals (AMEX: RNN)
- Silence Therapeutics (AIM: SLN)
- Starpharma (ASX: SPL)
- Stirling Products Limited (ASX: STI)
